Taiho Oncology, Inc.
BiotechPrinceton, New Jersey, United States · Est. 2011
Taiho Oncology is a subsidiary of Otsuka Pharmaceutical Company focused on developing and commercializing innovative oncology medicines.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
8
Indications↗
Distinct diseases across all programs
73
Clinical Trials↗
All sponsored trials (all statuses)
3
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Phase 33
Phase 22
Phase 12
Preclinical1
By Therapeutic Area
top 2
Oncology
467%
Hematology
117%
R&D Momentum
47/100
Pipeline Velocity
11/100
Trial Completion Rate
57/100
Pipeline Concentration
50/100
Pipeline Freshness
59/100
Strategic Signals
- ↗Active in Hematology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Sep 2, 2026TrialPhase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
Sep 2, 2026TrialA Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
Sep 2, 2026TrialAn Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
Aug 27, 2026TrialA Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)
Jul 31, 2026TrialRandomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Jul 29, 2026TrialAn Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Jul 29, 2026TrialAn Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study
4 more events
Jul 10, 2026TrialA Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma
Jun 27, 2026TrialA Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
Oct 15, 2025FDALytgobi — LYTGOBI
Apr 17, 2024FDALytgobi — LYTGOBI
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
Oncologygastrointestinal cancerbreast cancer
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology
Oncology
Hematology
Oncology
Advanced Cancer
ASTX660Phase 1
Myeloid Neoplasm
ASTX030Phase 3
CedazuridinePhase 3
Unknown / Other
Regulatory
Regulatory Timeline
20222 events
FDASep 30
Lytgobi — LYTGOBI
Application NDA214801 (NDA)
FDASep 30
Lytgobi — LYTGOBI
Application NDA214801
20241 event
FDAApr 17
Lytgobi — LYTGOBI
Application NDA214801
20251 event
FDAOct 15
Lytgobi — LYTGOBI
Application NDA214801
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)